NCT00799682View on ClinicalTrials.gov

Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z®

PHASE4CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

January 31, 2011

Study Completion Date

February 28, 2011

Conditions
Dry Eye Disease
Interventions
DRUG

Xalatan

0.005% 1 drop in each eye daily between 7:00 p.m. and 9:00 p.m.

DRUG

Travatan Z

0.004%, 1 drop in each eye daily between 7:00 p.m. and 9:00 p.m.

Trial Locations (5)

11554

Ophthalmic Consultants of Long Island, East Meadow

11563

Ophthalmic Consultants of Long Island, Lynbrook

11570

Ophthalmic Consultants of Long Island, Rockville Centre

11581

Ophthalmic Consultants of Long Island, Valley Stream

11790

Ophthalmic Consultants of Long Island, Stony Brook

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Ophthalmic Consultants of Long Island

OTHER

NCT00799682 - Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z® | Biotech Hunter | Biotech Hunter